株探米国株
英語
エドガーで原本を確認する
6-K 1 a6kcovergsk-6610d.htm DIRECTOR/PDMR SHAREHOLDING a6kcovergsk-6610d

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of February 2024
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
 
 
GSK plc (the 'Company')
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Emma Walmsley
 
b)
Position/status
Chief Executive Officer
 
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
 
 
The vesting of Ordinary Shares awarded in 2019 under the Company's 2017 Performance Share Plan and subject to an additional vesting period of two years from the normal vesting date  
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£0.00
297,428.535
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
e)
Date of the transaction
2024-02-16
 
f)
Place of the transaction
 
N/A
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Emma Walmsley
 
b)
Position/status
Chief Executive Officer
 
c)
Initial notification/ amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan and subject to an additional vesting period of two years from the normal vesting date 
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.5797
​
139,792
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
e)
Date of the transaction
2024-02-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: February 19, 2024
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc